Jehad Charo
Schlieren, ZH, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Detecting Inter-Individual Contamination and Mismatches in Multiomics Next-Generation Sequencing Data.
Journal: Journal of visualized experiments : JoVE
Published: May 04, 2026
Target receptor expression dictates the selective intra-tumoral targeting of CD8+ T cells by eciskafusp alfa in matched PBMCs and TILs from CPI-naïve patients.
Journal: Frontiers in immunology
Published: March 31, 2026
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.
Journal: Journal for immunotherapy of cancer
Published: February 02, 2026
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: December 01, 2025
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors.
Journal: ESMO open
Published: November 05, 2025
Editorial: Community series in biomarkers in the era of cancer immunotherapy: zooming in from periphery to tumor microenvironment, volume II.
Journal: Frontiers in immunology
Published: July 08, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 01, 2025
Machine learning identifies clinical tumor mutation landscape pathways of resistance to checkpoint inhibitor therapy in NSCLC.
Journal: Journal for immunotherapy of cancer
Published: February 03, 2025
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.
Journal: Cancer research communications
Published: December 17, 2024
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 26, 2024
Investigating the complex interplay between fibroblast activation protein α-positive cancer associated fibroblasts and the tumor microenvironment in the context of cancer immunotherapy.
Journal: Frontiers in immunology
Published: December 08, 2023
Last Updated: 09/26/2026